Dr. Robert F. Kushner from Northwestern University discusses new weight-loss drugs for obesity management. Topics include nutrient-stimulated hormone-based meds, less common medications, comparing terzepatide to semaglutide, and future weight loss drug advancements. The focus is on improving overall health outcomes with successful interventions.

Dr. Robert Kushner, a Professor of Medicine at Northwestern University and founder of the American Board of Obesity Medicine, discusses the revolutionary weight loss drug Ozempic, which has gained popularity despite some skepticism. He highlights findings from the pivotal clinical trial on semaglutide, emphasizing its potential as a game-changer in obesity treatment. Will Bulsiewicz, ZOE's U.S. Medical Director, adds insights on the importance of gut health and personalized nutrition, advocating for a holistic approach to weight management.

Dr. Robert Kushner, an expert in weight management and the Medical Director at Northwestern Medicine, shares insights on the remarkable weight loss drug semaglutide. He explains how this medication mimics a natural hormone to reduce appetite and enhance feelings of fullness. The discussion dives into the implications of obesity as a disease, compares semaglutide with older weight-loss drugs, and emphasizes the importance of combining medication with lifestyle changes. Kushner also addresses the financial barriers to accessing obesity treatment.